#### IV model

##### MacGilchrist et al. 
Drug specific parameters were fixed within from the healthy midazolam PBPK model. Physiological alterations within hepatic impairment were applied to the model and simulations were conducted for virtual patients with stages of liver impairment classified as Child-Pugh A to C, corresponding to the patient demographics in the study by MacGilchrist, Birnie (31). Child-Pugh prognostication was not documented within this study, and limited clinical variables were reported to fully assess Child-Pugh status. Based on the clinical variables that were reported (i.e., total bilirubin, albumin), the study population likely consisted of patients representing each Child-Pugh classification. Therefore, for the population HI-PBPK model simulations for intravenous midazolam each Child-Pugh score was evaluated against observed data. Additionally, predicted clearance (mL/min/kg) and elimination half-life (h) was compared to control subjects. Participant demographics included within the study by MacGilchrist, Birnie (31) used for population PBPK simulations may be found in Table 2. 

**Table 2. HI population demographics for midazolam IV administration**

| **Study** | **Dose and administration** | **Cohort** | **N** | **Age (years)** | **Weight (kg)** |
|--|--|--|--|--|--|
| Macgilchrist, Birnie (42) | 0.075 mg/kg IV bolus | European patients with estimated Child-Pugh scores A-C | 7 | 39-54 | 71.3 ± 4.3 |
| Pentikäinen, Välisalmi (43) | 7.5 mg IV bolus | European male patients with estimated Child-Pugh scores B and C | 7 | 48 ± 13.9 | 85.1 ± 12.2 |

Simulated PK of midazolam administered as a 0.075 mg/kg IV bolus in patients with Child-Pugh A, B, and C are presented in **Figure 1**, **Figure 2**, and **Figure 3**, respectively. An evaluation of predicted versus observed PK parameters from patients enrolled in Macgilchrist, Birnie (42) is presented in **Table 3**. 

**Table 3. Evaluation of midazolam IV HI-PBPK model-predicted vs observed PK parameters from Macgilchrist, Birnie (42)**

| **Study** | **Predicted clearance (mL/min/kg)** | **Observed clearance (mL/min/kg)** | **Fold-error** | **Predicted half-life (h)** | **Observed half-life (h)** | **Fold-error** | 
|--|--|--|--|--|--|--|
| Macgilchrist, Birnie (42), control | 6.3 | 10.4 ± 1.3 | 0.61 | 2.67 | 1.6 ± 0.3 | 1.67 |
| Macgilchrist, Birnie (42), HI population | Child-Pugh A: 4.85; B: 2.93; C: 1.85 | 5.4 ± 1 | A: 0.89; B: 0.54; C: 0.34 | A: 3.58; B: 5.64; C: 10.5 | 3.9 ± 0.8 | A: 0.92; B: 1.45; C: 2.69 |

Simulated PK of midazolam administered as a 7.5 mg IV bolus in patients with Child-Pugh B and C are presented in **Figure 3** and **Figure 4**, respectively. An evaluation of predicted versus observed AUC<sub>∞</sub> and clearance from patients enrolled in Pentikäinen, Välisalmi (43) is presented in **Table 4**. 

**Table 4. Evaluation of midazolam IV HI-PBPK model-predicted predicted vs observed AUC<sub>∞</sub> and clearance from Pentikäinen, Välisalmi (43)**

| **Study** | **Predicted AUC<sub>∞</sub> (µg•h/L)** | **Observed AUC<sub>∞</sub> (µg•h/L)** | **Fold-error** | **Predicted clearance (mL/min/kg)** | **Observed clearance (mL/min/kg)** | **Fold-error** |
|--|--|--|--|--|--|--|
| Pentikäinen, Välisalmi (43), control | 296.61 | 298 ± 25 | 0.99 | 5.81 | 5.63 ± 0.43 | 1.04 |
| Pentikäinen, Välisalmi (43), HI population | Child-Pugh B: 698.45; C: 1171.57 | 543 ± 93 | B: 1.29; C: 2.16 | B: 2.35; C: 1.54 | 3.34 ± 0.6 | B: 0.7; C: 0.46 |

#### Oral model

Two studies, Pentikäinen, Välisalmi (43) and Andersen, Pedersen (44), were used to evaluate the HI-PBPK model with oral administration (**Table 5**). Unlike Macgilchrist, Birnie (42) and Pentikäinen, Välisalmi (43), Andersen, Pedersen (44) categorized their patients based on Child-Pugh scores A-C. 

**Table 5. HI population demographics for midazolam oral administration**

| **Study** | **Dose and administration** | **Cohort** | **N** | **Age (years)** | **Weight (kg)** |
|--|--|--|--|--|--|
| Pentikäinen, Välisalmi (43) | 15 mg oral single dose 3 days after receiving IV bolus | European male patients with estimated Child-Pugh scores B and C | 7 | 48 ± 13.9 | 85.1 ± 12.2 |
| Andersen, Pedersen (44) | 15 mg oral single dose | European females (30%) and males with Child-Pugh A-C | A: 6; B: 1; C: 3 | 30-79 | Not reported |

Simulated PK of midazolam administered as a 15 mg oral single dose in patients with Child-Pugh B and C are presented in **Figure 4** and **Figure 5**, respectively. An evaluation of predicted versus observed AUC<sub>∞</sub> and Cmax from patients enrolled in Pentikäinen, Välisalmi (43) is presented in **Table 6**. 

**Table 6. Evaluation of midazolam oral HI-PBPK model-predicted predicted vs observed AUC<sub>∞</sub> and Cmax from Pentikäinen, Välisalmi (43)**

| **Study** | **Predicted AUC<sub>∞</sub> (µg•h/L)** | **Observed AUC<sub>∞</sub> (µg•h/L)** | **Fold-error** | **Predicted Cmax (µg/L)** | **Observed Cmax (µg/mL)** | **Fold-error** |
|--|--|--|--|--|--|--|
| Pentikäinen, Välisalmi (43), control | 260.9 | 362 ± 61 | 0.72 | 70.69 | 90 ± 14 | 0.79 |
| Pentikäinen, Välisalmi (43), HI population | Child-Pugh B: 880.49; C: 1289.16 | 576 ± 89 | B: 1.53; C: 2.24 | B: 76.96; C: 54.04 | 129 ± 24 | B: 0.59; C: 0.41 |

Finally, an evaluation of predicted versus observed AUC<sub>∞</sub> and Cmax from patients enrolled in Andersen, Pedersen (44) is presented in **Table 7**. 

**Table 7. Evaluation of midazolam oral HI-PBPK model-predicted predicted vs observed AUC<sub>∞</sub> and Cmax from Andersen, Pedersen (44)**

| **Study** | **Predicted AUC<sub>∞</sub> (µg•h/L)** | **Observed AUC<sub>∞</sub> (µg•h/L)** | **Fold-error** | **Predicted Cmax (µg/L)** | **Observed Cmax (µg/mL)** | **Fold-error** |
|--|--|--|--|--|--|--|
| Andersen, Pedersen (44), HI population | Child-Pugh A: 19507.72; B: 65209.07; C: 79644.66 | 24700 | A: 0.79; B: 2.64; C: 3.22 | A: 57.92; B: 97.06; C: 56.21 | 87 | A: 0.67; B: 1.12; C: 0.65 |